Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2003
05/28/2003EP0971713B1 Use of cholinesterase inhibitors to treat disorders of attention
05/28/2003EP0934061B1 Isobutylgaba and its derivatives for the treatment of pain
05/28/2003EP0814828B1 Method of preparation a therapeutic agent for the regeneration of oligodendrocytes
05/28/2003EP0814792B1 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
05/28/2003EP0814789B1 Pharmaceutical compositions comprising monoamine oxidase b inhibitors
05/28/2003EP0788509B1 Therapeutic peptide derivatives
05/28/2003EP0786995B1 Use of 5-(tetradecyloxy)-2-furan carboxylic acid for treating alzheimer's disease or psychosis
05/28/2003CN1420891A Pharmaceutical compound
05/28/2003CN1420888A Substd. pyrazoloÒÇö4,3-eÒÇòdiazepines, pharmaceu-tical compositions contg. them, use as medicinal products and processes for preparing them
05/28/2003CN1420887A 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors
05/28/2003CN1420886A (5R)-(methylamino)-5,6-dihydro-4H-imidazo ÒÇö4,5,1-ijÒÇòquinoline-2 (1H)-thione
05/28/2003CN1420885A Therapeutically useful new salts of CCK inhibitors, process for preparation thereof and pharmaceutical preparations contg. them
05/28/2003CN1420883A N-aryl-(homopiperazinyl) cyclohexyl amines as 5-HT transporters
05/28/2003CN1420882A Substd. oxoazaheterocyclyl compounds
05/28/2003CN1420881A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha
05/28/2003CN1420878A Compound with growth hormone releasing properties
05/28/2003CN1420872A Caspase inhibitors and use thereof
05/28/2003CN1420870A Modulators of dopamine neurotransmission
05/28/2003CN1420869A Modulators of dopamine neurotransmission
05/28/2003CN1420790A Transporters and drug delivery system by using same
05/28/2003CN1420785A Method of treating cancer with anti-neurotrophin agents
05/28/2003CN1420779A Nucleoside analogs with carboxamidine-modified bicyclic base
05/28/2003CN1420770A Method of delivery of cetyl myristoleate
05/28/2003CN1420723A Compositions and methods for L-nucleosides, and their analogs
05/28/2003CN1420114A 2,3-disubstd. -4(3H)-quinazolones
05/28/2003CN1109680C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
05/28/2003CN1109675C Arylpyrimidine derivs.
05/28/2003CN1109543C Pharmaceutical prepn. comprising eicosapentaenoic acid and/or stearidonic acid
05/28/2003CN1109542C Improved nicotine lozenge and therapeutic method for smoking cessation
05/27/2003US6570002 Inhibitor of programmed cell death
05/27/2003US6569996 Antibody that specifically binds to the cadherin-5 cell adhesion recognition sequence
05/27/2003US6569904 Via administration of toremifene for treatment or prevention of systemic/pulmonary hypertension, fibrosis, bronchial asthma, respiratory distress syndrome, myocardial infarction, thrombosis, congestive heart failure, and renal failure
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569888 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis
05/27/2003US6569887 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
05/27/2003US6569885 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569884 Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569861 Melanin concentrating hormone receptor ligands
05/27/2003US6569850 Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tyrptophan and possibly a vitamin B12 compound
05/27/2003US6569849 N-Substituted azaheterocyclic compounds
05/27/2003US6569842 Method of preparing and use of prodrugs of betulinic acid derivatives
05/27/2003US6569665 Genetic engineering; enzymatic inhibitor screening; use of calpain inhibitors in treatment of neurodegenerative disease
05/27/2003US6569470 Monoamine oxidase (MAO) inhibitors and uses thereof
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569431 Polypeptide for use in the treatment of autoimmune disease and multiple sclerosis
05/27/2003CA2412624A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurogenerative diseases
05/27/2003CA2412466A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/27/2003CA2268847C Substituted oximes derivatives useful as neurokinin antagonists
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2110119C Antiinflammatory and analgesic gel preparation
05/27/2003CA2104297C 4-sulfanimide-quinoline nmda antagonists
05/22/2003WO2003042405A2 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
05/22/2003WO2003042397A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042384A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof
05/22/2003WO2003042381A1 Three-dimensional structure of prostaglandin d synthase and utilization thereof
05/22/2003WO2003042377A1 Expansion of t cells in vitro and expanded t cell populations
05/22/2003WO2003042362A2 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
05/22/2003WO2003042359A2 Histamine receptor h3 polynucleotides
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042211A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003WO2003042210A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003WO2003042208A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042202A1 Isobenzofuran derivatives
05/22/2003WO2003042194A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042182A1 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
05/22/2003WO2003042178A1 Novel piperidine derivatives as modulators of chemokine receptors
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042175A1 Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042173A1 Nk1 antagonists
05/22/2003WO2003042164A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042162A1 Prodrugs of antidepressants and their use for treating depressions
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041721A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041713A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
05/22/2003WO2003041708A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041701A2 Preparation for improving the action of receptors
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041649A2 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003WO2003041563A2 Neurotransmitter balance chemotherapy
05/22/2003WO2003018004A3 Analgetic pyrroline derivatives
05/22/2003WO2003012089A3 Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
05/22/2003WO2002100350A3 Dopamine receptor ligands and therapeutic methods based thereon
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002096362A3 Method for treating fibrotic diseases or other indications vi
05/22/2003WO2002076390A3 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
05/22/2003WO2002045749A8 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
1 ... 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 ... 1833